Compare RLX Technology Inc (RLX) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
RLX Technology Inc vs Tempus AI — how do they compare? RLX Technology Inc trades at $1.73 (market cap $2.11B), while Tempus AI trades at $69.99 (market cap $12.77B). The key difference: Tempus AI is far larger — about 6.1× RLX Technology Inc's market cap, and RLX Technology Inc pays a 5.78% dividend while Tempus AI pays none. Which is the better fit depends on your goals — on Pluang, investors hold RLX Technology Inc for 34 Days and Tempus AI for 22 Days on average.
| RLX | TEM | |
|---|---|---|
Market Cap | $2.11B | $12.77B |
Volume | 621,808 | 8,980,490 |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $2.57 | $99.28 |
52-Week Low | $1.68 | $41.55 |
Typical Hold Time | 34 Days | 22 Days |
Enterprise Value | $844.50M | $13.40B |
Dividend Yield | 5.78% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RLX Technology trades at $1.73, down 1.76% with a bearish technical signal. The stock recently hit 52-week lows amid margin compression despite 14.8% revenue growth in Q2 2026. Valuation appears reasonable with P/E of 15.55 and P/B below 1, but earnings misses in recent quarters raise execution concerns. International expansion now drives 70% of revenue following European acquisitions.
The outlook remains challenged by consecutive earnings misses and technical weakness, though discounted valuation and international growth provide potential upside. Key risks include sustained margin pressure and integration challenges from recent acquisitions. With only one analyst covering and maintaining a hold rating, institutional conviction appears limited.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite negative profitability. Recent FDA clearance for its ECG-MR AI product and 13 abstracts accepted for ESMO Congress 2026 highlight ongoing innovation. Revenue grew to $1.4B in 2026, though net losses persist. The stock shows strong analyst support with a $72.60 consensus target and 64% buy ratings.
Outlook remains cautiously optimistic driven by AI healthcare adoption and data licensing growth, but high valuation multiples and sustained losses pose risks. Investor sentiment is positive amid recent insider selling and institutional interest, yet profitability challenges and competitive pressures require monitoring for long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
